Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4684-3
Abstract: PurposeLeptomeningeal disease is a rare and devastating presentation of advanced stage metastatic breast cancer with historically poor overall survival. We assessed the safety and feasibility of intrathecal (IT) trastuzumab in HER2+ leptomeningeal disease.MethodsA total of… read more here.
Keywords: intrathecal trastuzumab; leptomeningeal disease; breast; disease ... See more keywords
HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen.
Sign Up to like & getrecommendations! Published in 2023 at "CNS oncology"
DOI: 10.2217/cns-2022-0018
Abstract: Materials & methods: We recently reported the largest trial of breast cancer patients with HER2 positive leptomeningeal metastases (LM) treated with trastuzumab. An additional treatment indication was explored as part of a single institution retrospective… read more here.
Keywords: leptomeningeal metastases; intrathecal trastuzumab; esophageal carcinoma; trastuzumab ... See more keywords